Today's pre-market stock movers: DWAC, GS, MU, EDU and more
Gainers:
• $Day One Biopharmaceuticals (DAWN.US)$ +67.7% (Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma)
• $Gracell Biotechnologies (GRCL.US)$ +12.1% (Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +6.1% (trading higher with US futures down over 2%+)
• $OptiNose (OPTN.US)$ +2.7% (top-line results of ReOpen2, its second phase 3 clinical trial of XHANCE for treatment of chronicsinusitis)
• $Ionis Pharmaceuticals (IONS.US)$ +2.6% (treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA)
• $Apellis Pharmaceuticals (APLS.US)$ +2.3% (receives FDA orphan designation for Pegcetacoplan, treatment of immune complex-membranoproliferative glomerulonephritis)
• $Mudrick Capital Acquisition Corp (MUDS.US)$ +0.7% (Blue Nile to combine with Mudrick Capital Acquisition Corporation II )
Analyst comments:
Losers:
• $Astra Space (ASTR.US)$ -21.8% (tweets "We had a nominal first stage flight. The upper stage shut dow nearly and we did not deliver the payloads to orbit. We have shared our regrets with NASA and the payload team. More information will be provided after we complete a full data review")
• $Cogent Biosciences (COGT.US)$ -12.7% (commenced an underwritten public offering of $125 million of shares of its common stock)
• $US Energy (USEG.US)$ -4.9% (files for 19905736 share common stock offering by selling shareholders)
• $Emeren Group (SOL.US)$ -3.5% (reports award of 20-year renewable energy credit contracts for two solar projects in New York and Illinois)
• $Photronics (PLAB.US)$ -3.3% (files to delay its 10-Q as the information required is not available as of the 10-Q required filing date)
• $Cenovus Energy (CVE.US)$ -3.1% (to purchase the remaining 50% of the Sunrise oil sands project in northern Alberta from bp)
• $Genmab (GMAB.US)$ -3% (reports late-breaking Phase 2 trial results of investigational Epcoritamab)
• $BeiGene (BGNE.US)$ -2.4% (has extended the Prescription Drug User Fee Actgoaldate by three months to January 20 2023 for the supplementary new drug application for BRUKINSA as a treatment for adult patients with chroniclymphocytic leukemia orsmall lymphocytic lymphoma)
(Briefing note - With US futures trading 2-3% lower, most stocks are trading down. The following represents decliners that have identified catalysts)
Analyst comments:
• $T. Rowe Price (TROW.US)$ -3.3% (downgraded to MarketPerform fromOutperform at BMOCapital Markets)
• $New Residential Investment (NRZ.US)$ -2.7% (downgraded to Underweight from Neutral at Piper Sandler)
Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.
Read more
Comment
Sign in to post a comment
Moomoo News Official Account
Explore and integrate top feeds before the bell
64KFollowers
14Following
64KVisitors
Follow
Giovanni Ayala :
SpyderCall : don't forget to mention the crash of the cryptocurrency Celsius which caused a meltdown in just about every other crypto
71018838 : No mention of RDBX up 30%???
Stuka II 71018838 : That’s way too thigh to chase, buddy
whqqq : It's all very detailed information![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")